XML 17 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Total revenue, net $ 228,614 $ 306,911 $ 369,193
Less: Cost of goods sold 110,758 102,142 108,631
Less: Cost of goods sold - restructuring inventory 36,474 39,228 18,078
Gross margin 81,382 165,541 242,484
Operating expenses:      
Selling, general and administrative 152,310 199,938 304,416
Research and development 20,869 22,219 30,411
Restructuring 0 10,972 13,526
Total operating expenses 173,179 233,129 348,353
Operating loss (91,797) (67,588) (105,869)
Interest income 13,403 11,863 2,819
Interest expense (7) (8) (15)
Other income (expense), net 1,201 2,063 (740)
Loss from operations before taxes (77,200) (53,670) (103,805)
Provision for income taxes (4,983) (5,442) (1,998)
Net loss $ (82,183) $ (59,112) $ (105,803)
Loss per share:      
Basic [1] $ (0.2) $ (0.15) $ (0.26)
Diluted [1] $ (0.20) $ (0.15) $ (0.26)
Weighted average shares outstanding:      
Basic 410,937 407,655 401,155
Diluted 410,937 407,655 401,155
Product Revenue, Net      
Total revenue, net $ 204,590 $ 285,299 $ 366,511
Licensing and Royalty Revenue      
Total revenue, net $ 24,024 $ 21,612 $ 2,682
[1] Excluding the licensing revenue change in estimate incurred in 2024 and the licensing revenue change in estimate and Medicaid change in estimate incurred in 2023, both discussed in Note 12 – Revenue Recognition, net loss per share basic and diluted for both years ended December 31, 2024 and 2023 would have been $(0.21).